Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 6/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.35 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31512600 | 0.93 | ACE2 (0.46) | TAAR1NPBWR1MAOBACE2PIM1 | |
| SCHEMBL18448706 | 0.85 | ACE2 (0.45) | ACE2PIM1PIM2CYBBNOX3 | |
| SCHEMBL31512644 | 0.81 | ACE2 (0.35) | TAAR1ACE2PIM1PIM2CYBB | |
| SCHEMBL31512653 | 0.79 | DAO (0.37) | TAAR1ACE2PIM1PIM2CYBB | |
| SCHEMBL18614108 | 0.78 | ALOX5 (0.59) | ACE2CYBBNOX3NOX4NOX1 | |
| SCHEMBL30811586 | 0.78 | KIF11 (0.49) | ACE2PIM1PIM2CYBBNOX3 | |
| SCHEMBL29636446 | 0.78 | ALOX5 (0.59) | ACE2CYBBNOX3NOX4NOX1 | |
| SCHEMBL27344289 | 0.78 | KIF11 (0.49) | ACE2PIM1PIM2CYBBNOX3 | |
| SCHEMBL31512579 | 0.76 | PNMT (0.43) | TAAR1MAOBLOXL2LOX | |
| SCHEMBL31512597 | 0.76 | MITF (0.39) | TAAR1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | SIRONAX BEIJING CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| CN-119866332-A | Iron death inhibitor-phenoxazine acetamides | 维泰瑞隆（北京）生物科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | AIFM2, GPX4, FECH | TAAR1 3211/4885NPBWR1 3766/4885MAOB 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.